Patent Allowance and Stock Reaction

Can-Fite Biopharma Ltd (NYSE American: CANF) saw its shares rise 13.3% on Friday following the Japan Patent Office’s allowance of Japanese Patent Application No. 2025‑049941. The patent authorises the use of the company’s drug candidate Namodenoson, an orally administered, highly selective A3 adenosine receptor agonist, for inducing fat loss and treating obesity and related metabolic disorders.

Scope of the Patent

The allowance covers the broader class of A3 adenosine receptor agonists, thereby extending protection to Namodenoson and similar compounds in Japan, one of the world’s largest pharmaceutical markets. This strengthens the company’s intellectual‑property position in a key jurisdiction.

Existing Global Patent Portfolio

Can‑Fite has already secured patent protection for the same technology in the United States, Canada, Australia and Israel. The robustness of the patent estate is underpinned by scientific evidence published in the International Journal of Obesity, which demonstrated Namodenoson’s anti‑obesity activity.

Drug Profile

Namodenoson is characterized by an established safety profile from clinical studies and a differentiated mechanism of action that targets pathways involved in adipogenesis, inflammation and metabolic regulation, offering a potential oral alternative to existing injectable obesity therapies.

Executive Commentary

Dr. Pnina Fishman, Chairperson and Chief Scientific Officer of Can‑Fite, stated that the Japanese patent allowance significantly strengthens the company’s global IP portfolio and enhances the value of Namodenoson as a differentiated oral therapeutic candidate for obesity and metabolic diseases.

Market Context

Industry forecasts project the global obesity therapeutics market to exceed $60 billion by 2030. Current therapies are often associated with gastrointestinal side effects, injectable administration, high discontinuation rates and elevated costs, underscoring the commercial relevance of an oral agent like Namodenoson.

Company Overview

Can‑Fite is a clinical‑stage biotechnology company developing a pipeline of proprietary small‑molecule drugs targeting oncological and inflammatory diseases.

Publication Note

The article was generated with AI assistance and reviewed by an editor.